アレルギー性鼻炎薬の世界市場2016-2020

◆英語タイトル:Global Allergic Rhinitis Drugs Market 2016-2020
◆商品コード:IRTNTR8279
◆発行会社(調査会社):Technavio
◆発行日:2016年2月10日
◆ページ数:90
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、アレルギー性鼻炎薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、アレルギー性鼻炎薬の世界市場規模及び予測、剤形別分析、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況などの情報をお届けいたします。
【レポートの概要】

About Allergic Rhinitis Drugs

Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.

Technavio’s analysts forecast the global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis.

The market is divided into the following segments based on geography:
• Americas
• APAC
• Europe

Technavio’s report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• GlaxoSmithKline
• Meda Pharmaceuticals
• Merck
• Sanofi
• UCB

[Other prominent vendors]
• Adamis Pharmaceuticals
• Alcon
• Alergo Pharma
• ALK-Abelló
• Allergy Therapeutics
• Almirall
• Ampio
• Anergis
• Apotex
• Ares Life Sciences
• Array BioPharma
• Aspen Pharmacare
• Atopix Therapeutics
• Barr Laboratories
• Belcher Pharmaceuticals
• Circassia Pharmaceuticals
• Dainippon Sumitomo
• DBV Technologies
• Dr Reddy’s Laboratories
• Eddingpharm
• Genentech
• Greer Laboratories
• Hanmi Pharmaceuticals
• Hisamitsu Pharmaceutical
• Intas Pharmaceuticals
• Kyowa Hakko
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Mylan
• Nektar Therapeutics
• Novartis
• Nuvo Research
• Nycomed
• Omega Pharma
• Ono Pharmaceuticals
• Pfizer
• Revance Therapeutics
• Roxane Laboratories (Boehringer Ingelheim)
• Shionogi
• Stallergenes
• Sun Pharmaceuticals
• Takeda Pharmaceutical
• Teva Pharmaceuticals
• Verona Pharma
• VentiRx Pharmaceuticals

[Market driver]
• Increased prevalence of allergic rhinitis
• For a full, detailed list, view our report

[Market challenge]
• Patent expiries and competition from generic drugs
• For a full, detailed list, view our report

[Market trend]
• Increased R&D
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Allergic rhinitis
• Understanding the disease
• Classification of allergic rhinitis
• Causes
• Signs and symptoms
• Risk factors
• Diagnosis and testing
• Treatment
• Epidemiology
• Economic burden and impact on quality of life

PART 06: Pipeline analysis
• Information on pipeline candidates
• Clinical trial information of allergic rhinitis

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation based on class of drugs
• Antihistamines
• Intranasal corticosteroids
• Immunotherapies
• Global antihistamines drugs market
• Global intranasal corticosteroids drugs market
• Global immunotherapies drugs market

PART 09: Market segmentation by route of administration
• Oral
• Parenteral
• Intranasal

PART 10: Market segmentation by dosage form
• Solid
• Liquid

PART 11: Geographical segmentation
• Global allergic rhinitis drugs market by geography 2015-2020
• Allergic rhinitis drugs market in Americas
• Allergic rhinitis drugs market in EMEA
• Allergic rhinitis drugs market in APAC

PART 12: Market drivers
• Increased prevalence of allergic rhinitis
• Rise in awareness about allergic rhinitis
• High usage of tobacco
• Presence of high unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges
• Increased preference for CAM
• Patent expiries and competition from generic drugs
• Adverse effects of drugs
• Poor patient adherence

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Self-medication using OTC products
• Increased R&D
• Intense competition
• Strategic alliances

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AstraZeneca
• GlaxoSmithKline
• Meda Pharmaceuticals
• Merck
• Sanofi
• UCB
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of allergic rhinitis
Exhibit 03: Risk factors associated with allergic rhinitis
Exhibit 04: Major diagnostic procedures for allergic rhinitis
Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Examples of non-pharmacological therapies
Exhibit 09: Treatment algorithm of allergic rhinitis
Exhibit 10: Prevalence of allergic rhinitis in China
Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio
Exhibit 12: Allergic rhinitis clinical trials by development phase 2015
Exhibit 13: Allergic rhinitis clinical trials by trial status 2015
Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Global allergic rhinitis market based on class of drugs
Exhibit 17: Examples of prescription and OTC intranasal corticosteroids
Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015
Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions)
Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions)
Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions)
Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions)
Exhibit 23: Global allergic rhinitis drugs market by route of administration
Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form
Exhibit 25: Global allergic rhinitis drugs market by geography 2015
Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Drivers of global allergic rhinitis drugs market
Exhibit 31: Impact of drivers
Exhibit 32: Challenges of global allergic rhinitis drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Trends of global allergic rhinitis drugs market
Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015
Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions)
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 46: GlaxoSmithKline: Key takeaways
Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014
Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 50: Meda Pharmaceuticals: Top-selling drugs
Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions)
Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions)
Exhibit 53: Meda Pharmaceuticals: Key takeaways
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Merck: Top-selling drugs
Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
Exhibit 61: Merck: Key takeaways
Exhibit 62: Sanofi: Business segmentation by revenue 2014
Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 64: Sanofi: Geographical segmentation by revenue 2014
Exhibit 65: Sanofi: Top-selling drugs
Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions)
Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions)
Exhibit 69: Sanofi: Key takeaways
Exhibit 70: UCB: Product segmentation by revenue 2014
Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 72: UCB: Geographical segmentation by revenue 2014
Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions)
Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions)
Exhibit 75: UCB: Key takeaways



【掲載企業】

AstraZeneca, GlaxoSmithKline, Meda Pharmaceuticals, Merck, Sanofi, UCB, Adamis Pharmaceuticals, Alcon, Alergo Pharma, ALK-Abello, Allergy Therapeutics, Almirall, Ampio, Anergis, Apotex, Ares Life Sciences, Array BioPharma, Aspen Pharmacare, Atopix Therapeutics, Barr Laboratories, Belcher Pharmaceuticals, Circassia Pharmaceuticals, Dainippon Sumitomo, DBV Technologies, Dr Reddy's Laboratories, Eddingpharm, Genentech, Greer Laboratories, Hanmi Pharmaceuticals, Hisamitsu Pharmaceutical, Intas Pharmaceuticals, Kyowa Hakko, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Mylan, Nektar Therapeutics, Novartis, Nuvo Research, Nycomed, Omega Pharma, Ono Pharmaceuticals, Pfizer, Revance Therapeutics, Roxane Laboratories (Boehringer Ingelheim), Shionogi, Stallergenes, Sun Pharmaceuticals, Takeda, Teva Pharmaceuticals, Verona Pharma, VentiRx Pharmaceuticals.

【レポートのキーワード】

アレルギー性鼻炎、免疫グロブリンE、治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[アレルギー性鼻炎薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年07月28日現在 197,496 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆